Compare COHN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COHN | ATNM |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3M | 45.2M |
| IPO Year | 2003 | 2013 |
| Metric | COHN | ATNM |
|---|---|---|
| Price | $14.50 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 9.2K | ★ 113.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.91% | N/A |
| EPS Growth | ★ 97.63 | 30.60 |
| EPS | ★ 3.61 | N/A |
| Revenue | ★ $79,598,000.00 | $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.10 | $1.02 |
| 52 Week High | $32.60 | $1.95 |
| Indicator | COHN | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 43.12 |
| Support Level | $10.72 | $1.02 |
| Resistance Level | $16.48 | $1.71 |
| Average True Range (ATR) | 0.88 | 0.08 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 10.54 | 45.36 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.